Michael Patrick Miller - 09 Jan 2026 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Reporting relationship: Director
Issuer ticker: BTAI
Reported as of: 09 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jan 2026, 19:02:53 UTC
Prior SEC filing: 13 Nov 2025
Next SEC filing: 03 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Richard Steinhart, Attorney-in-Fact for Michael Patrick Miller

Key filing fact

Michael Patrick Miller filed Form 4 for BioXcel Therapeutics, Inc. (BTAI) on 12 Jan 2026.

Key facts

This page summarizes Michael Patrick Miller's Form 4 filing for BioXcel Therapeutics, Inc. (BTAI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Jan 2026, 19:02.

Change

Previous filing in this sequence was filed on 13 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001236514 Primary reporting owner

MILLER MICHAEL PATRICK

Relationship: Director
Address: C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, 12TH FLOOR, NEW HAVEN
Signature: /s/ Richard Steinhart, Attorney-in-Fact for Michael Patrick Miller
Signature date: 12 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BTAI transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +17,000
Change %
Price: $0.000000
Shares after: 17,000
Date: 09 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,000
Exercise price: $2.01
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date.